Glenn Harvey
Illustrator
From this contributor
How long-read sequencing will transform neuroscience
New technology that delivers much more than a simple DNA sequence could have a major impact on brain research, enabling researchers to study transcript diversity, imprinting and more.
How long-read sequencing will transform neuroscience
What kind of autism research should we do, and where should we do it?
Researchers at INSAR 2023 need to discuss these questions and remember that the purpose of research may be different for different communities.
What kind of autism research should we do, and where should we do it?
New measure characterizes gender diversity in study participants
The Gender Self-Report could help autism researchers include more gender-diverse people across a range of ages and neurotypes in their work.
New measure characterizes gender diversity in study participants
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
Debut drug for Rett syndrome at edge of approval
Explore more from The Transmitter
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.